Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-08-13Clinical Trial Update: Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
A Phase 1 trial evaluating venetoclax and navitoclax with cladribine-based salvage therapy for relapsed/refractory acute myeloid leukemia ha…
-
CLINICAL_TRIALS withdrawal · 2024-08-07Clinical Trial Update: ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML [Phase 1]
A Phase 1 trial of ELU001 for CBFA2T3-GLIS2-positive pediatric acute myeloid leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-07-29Clinical Trial Update: Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia [Phase 3]
Phase 3 trial evaluating uproleselan (GMI-1271) in combination with chemotherapy for relapsed/refractory acute myeloid leukemia has been ter…
-
CLINICAL_TRIALS withdrawal · 2024-06-28Clinical Trial Update: Managed Access Programs for PKC412, Midostaurin
This update indicates that Novartis' managed access programs for midostaurin (PKC412) are no longer available, impacting access for patients…
-
CLINICAL_TRIALS withdrawal · 2024-06-14Clinical Trial Update: Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant [Phase 2]
A Phase 2 trial evaluating adding venetoclax to high-dose chemotherapy before a mismatched allogeneic stem cell transplant for acute myeloid…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-05-23Clinical Trial Update: Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML
The clinical trial NCT05309018 evaluating the integration of an advanced practice nurse in the complex care pathway for patients with acute …
-
CLINICAL_TRIALS withdrawal · 2024-04-29Clinical Trial Update: High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD [Phase 1, Phase 2]
The trial update indicates that the Phase 1/2 study of high-dose post-transplant cyclophosphamide, bortezomib, and sitagliptin for preventio…
-
EMA withdrawal · 2023-06-21EMA Application withdrawn: Tidhesco (Ivosidenib) — Les Laboratoires Servier
The EMA withdrew the application for Tidhesco (ivosidenib) by Les Laboratoires Servier for acute myeloid leukemia therapeutic use.
-
CLINICAL_TRIALS withdrawal · 2022-05-25Clinical Trial Update: Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML [Phase 3]
Phase 3 trial comparing daunorubicin or idarubicin with cytarabine plus quizartinib versus physician's choice in newly diagnosed FLT3-ITD+ a…
-
CLINICAL_TRIALS withdrawal · 2021-04-27Clinical Trial Update: Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT [Phase 3]
Phase 3 randomized trial evaluating standard of care with or without atorvastatin for prevention of graft-versus-host disease in matched unr…
-
EMA withdrawal · 2021-04-16EMA Application withdrawn: Tibsovo (Ivosidenib) — Agios Netherlands B.V.
The EMA has withdrawn the applicant for Tibsovo (ivosidenib) by Agios Netherlands B.V. for acute myeloid leukemia.
-
CLINICAL_TRIALS withdrawal · 2019-02-20Clinical Trial Update: Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) [Phase 1, Phase 2]
The clinical trial evaluating the combination of azacitidine and avelumab in patients with acute myeloid leukemia and minimal residual disea…
-
CLINICAL_TRIALS withdrawal · 2018-07-24Clinical Trial Update: Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating PD-616 in combination with cytarabine for acute myeloid leukemia and myelodysplastic syndromes has bee…
-
CLINICAL_TRIALS withdrawal · 2018-07-03Clinical Trial Update: 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating 6,8-Bis(Benzylthio)Octanoic Acid in combination with Cytarabine and Daunorubicin hydrochloride for unt…
-
CLINICAL_TRIALS withdrawal · 2018-07-02Clinical Trial Update: Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia [Phase 2]
Phase 2 trial of gemtuzumab ozogamicin for adults with acute myeloid leukemia, including acute promyelocytic leukemia and various cytogeneti…
-
CLINICAL_TRIALS withdrawal · 2018-05-21Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
A Phase 2 trial of arsenic trioxide for relapsed or refractory acute myeloid leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-05-04Clinical Trial Update: Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant [Phase 2]
A Phase 2 study of midostaurin in older patients with AML with gene mutations after transplant has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-05-04Clinical Trial Update: Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia [Phase 1]
A phase 1 trial evaluating volasertib in combination with induction chemotherapy for acute myeloid leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-04-19Clinical Trial Update: Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia [Phase 1]
A Phase 1 study of dasatinib in combination with chemotherapy for relapsed or refractory core-binding factor acute myeloid leukemia has been…
-
CLINICAL_TRIALS withdrawal · 2018-03-30Clinical Trial Update: Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS [Phase 2]
A Phase II study evaluating maintenance therapy with 5-azacitidine after stem cell transplant in acute myeloid leukemia or myelodysplastic s…
-
CLINICAL_TRIALS withdrawal · 2018-03-14Clinical Trial Update: Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment [Phase 2]
Clinical trial update notes that a Phase 2 study evaluating the pharmacokinetics and pharmacodynamics of CPX-351 in acute leukemias and myel…
-
CLINICAL_TRIALS withdrawal · 2018-03-06Clinical Trial Update: Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
The Phase 1 trial of Minnelide in adults with relapsed or refractory acute myeloid leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-12-05Clinical Trial Update: StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies [Phase 2]
Phase 2 trial evaluating StemRegenin-1-expanded versus unexpanded umbilical cord blood for high-risk hematologic malignancies has been withd…
-
CLINICAL_TRIALS withdrawal · 2017-12-02Clinical Trial Update: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies [Phase 1, Phase 2]
A trial investigating T-regulatory cell and CD3-depleted double umbilical cord blood transplantation for hematologic malignancies has been w…
-
CLINICAL_TRIALS withdrawal · 2017-12-02Clinical Trial Update: CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission [Phase 2]
A Phase 2 trial evaluating haploidentical donor natural killer cell therapy using CD3/CD19-depleted or CD3-depleted/CD56-selected NK cells f…